Mylan launches generic version of Novartis’ Exelon Patch

11 July 2018 (Last Updated July 11th, 2018 11:49)

Mylan has launched Rivastigmine Transdermal System, a generic version of Novartis' Exelon Patch, for the treatment of patients suffering from dementia in the US.

Mylan has launched Rivastigmine Transdermal System, a generic version of Novartis’ Exelon Patch, for the treatment of patients suffering from dementia in the US.

The system expands Mylan’s central nervous system portfolio and is available in 4.6mg/24 hours, 9.5mg/24 hours and 13.3mg/24 hours variants.

The company’s abbreviated new drug application (ANDA) was approved by the US Food Drug Administration (FDA) for dementia in patients with mild, moderate and severe Alzheimer’s disease, as well as to treat mild to moderate dementia caused by Parkinson’s disease.

Mylan president Rajiv Malik said: “The launch of generic Exelon Patch is another example of the investment Mylan is continuing to make into products that are difficult to develop and manufacture, particularly in transdermal drug-delivery systems.

“The launch of this product also strengthens the company’s growing central nervous system portfolio, which is a therapeutic area of continued focus for Mylan as we strive to provide better health for a better world.”

The company offers approximately 7,500 generic and brand medicines worldwide across areas such as  oncology, respiratory, allergy and dermatology.

It has begun research and development work to grow its expertise in complex medicines, including biosimilars, antiretrovirals and transdermals.

“The launch of this product also strengthens the company’s growing central nervous system portfolio.”

Last month, Mylan launched a generic medicine called Bivalirudin for Injection in the US. This 250mg single-dose vial product is a generic version of The Medicines Company’s Angiomax.

Bivalirudin for Injection is a direct thrombin inhibitor indicated as an anticoagulant in patients having unstable angina and undergoing percutaneous transluminal coronary angioplasty.

The product can also be used in people undergoing percutaneous coronary intervention (PCI) involving provisional use of glycoprotein IIb/IIIa inhibitor (GPI).

Patients with or at risk of heparin-induced thrombocytopenia (HIT) or heparin induced thrombocytopenia and thrombosis syndrome (HITTS) and undergoing PCI can also be administered with Bivalirudin for Injection.